{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:50:24Z","timestamp":1789498224212,"version":"build-2803163510"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["por-journal.com"],"crossmark-restriction":true},"short-container-title":["Pathol. Oncol. Res."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Hairy cell leukemia (HCL) is an indolent B-cell lymphoproliferative disease. Interferon-alpha (IFN-alpha) was the first successfully used drug in HCL; its favourable effect has been known since the early 1980s. However, currently the first-line treatment of the disease consists of purine nucleoside analogs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>The aim of our study was to assess the efficacy of pegylated IFN-alpha in HCL patients treated with this drug at a single university center.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We report the treatment characteristics and outcome of seven classical HCL patients treated with pegylated IFN-alpha at the Department of Internal Medicine and Oncology, Semmelweis University.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>As a result of pegylated interferon-alpha treatment, 3 of 7 patients (3\/7) achieved an unconfirmed complete remission, 3 of 7 patients (3\/7) achieved partial remission. One patient had stable disease while receiving pegylated IFN-alpha. Only mild adverse effects and no infectious complications were observed during our treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our clinical data support that pegylated IFN-alpha in monotherapy is effective and safe even in elderly and frail HCL patients. It may also be a preferred therapeutic option in patients with profound immunosuppression and in patients with severe active infections.<\/jats:p><\/jats:sec>","DOI":"10.3389\/pore.2025.1612108","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T08:41:09Z","timestamp":1747816869000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Successful treatment of hairy cell leukaemia with pegylated interferon-alpha-2A"],"prefix":"10.3389","volume":"31","author":[{"given":"Kata","family":"Ferenczi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zs\u00f3fia Fl\u00f3ra","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ildik\u00f3","family":"Istenes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Eid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Csaba","family":"B\u00f6d\u00f6r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Botond","family":"Tim\u00e1r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit","family":"Demeter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1556\/OH.2013.29531","article-title":"Visszat\u00e9r\u0151 szomatikus mut\u00e1ci\u00f3 hajas sejtes leuk\u00e9mi\u00e1ban [Recurrent somatic mutation in hairy cell leukemia]","volume":"154","author":"S\u00e1ri","year":"2013","journal-title":"Orv Hetil"},{"key":"B2","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1002\/ajh.27240","article-title":"Hairy cell leukemia 2024: update on diagnosis, risk-stratification, and treatment\u2014annual updates in hematological malignancies","volume":"99","author":"Troussard","year":"2024","journal-title":"Am J Hematol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1182\/blood-2016-01-689422","article-title":"Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia","volume":"129","author":"Grever","year":"2017","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s11912-020-00911-0","article-title":"Hairy cell leukaemia","volume":"22","author":"Cross","year":"2020","journal-title":"Curr Oncol Rep"},{"key":"B5","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1002\/ajh.26390","article-title":"Hairy cell leukemia 2022: update on diagnosis, risk-stratification, and treatment","volume":"97","author":"Troussard","year":"2022","journal-title":"Am J Hematol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1056\/NEJMoa1014209.BRAF","article-title":"BRAF mutations in hairy-cell leukemia","volume":"364","author":"Tiacci","year":"2011","journal-title":"N Engl J Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1002\/ajh.25653","article-title":"Hairy cell leukemia: 2020 update on diagnosis, risk stratification, and treatment","volume":"94","author":"Maitre","year":"2019","journal-title":"Am J Hematol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"956","DOI":"10.3390\/cancers14040956","article-title":"Treatment of classic hairy cell leukemia: targeting minimal residual disease beyond cladribine","volume":"14","author":"Bohn","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1611378","DOI":"10.3389\/pore.2023.1611378","article-title":"Long term follow-up of refractory\/relapsed hairy cell leukaemia patients treated with low-dose vemurafenib between 2013 and 2022 at the Department of Internal Medicine and Oncology, Semmelweis University","volume":"29","author":"Ferenczi","year":"2023","journal-title":"Semmelweis Univ Pathol Oncol Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"v100","DOI":"10.1093\/annonc\/mdv200","article-title":"Hairy cell leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Robak","year":"2015","journal-title":"Ann Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.3390\/cancers14051242","article-title":"Hairy cell leukemia patients have a normal life expectancy\u2014a 35-year single-center experience and comparison with the general population","volume":"14","author":"Bohn","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1182\/blood.v92.6.1918","article-title":"Long-term follow-up of patients with hairy cell leukemia after cladribine treatment","volume":"92","author":"Saven","year":"1998","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1182\/blood-2017-12-820381","article-title":"Relative survival reaches a plateau in hairy cell leukemia: a population-based analysis in The Netherlands","volume":"131","author":"Dinmohamed","year":"2018","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S1521-6926(02)00084-1","article-title":"Interferon in the treatment of hairy-cell leukemia","volume":"16","author":"Ahmed","year":"2003","journal-title":"Best Pract Res Clin Haematol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/j.1600-0609.2008.01190.x","article-title":"Long-term follow-up of interferon-alpha induction and low-dose maintenance therapy in hairy cell leukemia","volume":"82","author":"Benz","year":"2009","journal-title":"Eur J Haematol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1034\/j.1600-0609.2000.90014.x","article-title":"Alpha-interferon as induction and maintenance therapy in hairy cell leukemia: a long-term follow-up analysis","volume":"64","author":"Damasio","year":"2000","journal-title":"Eur J Haematol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1182\/blood.v75.3.812.bloodjournal753812","article-title":"Minimal interferon-alpha doses for hairy cell leukemia","volume":"75","author":"Gastl","year":"1990","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s12254-016-0269-1","article-title":"Long-term treatment of hairy cell leukemia with interferon-\u03b1: still a viable therapeutic option","volume":"9","author":"Bohn","year":"2016","journal-title":"Memo - Mag Eur Med Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/bjh.17440","article-title":"The current role of interferon in hairy cell leukaemia: clinical and molecular aspects","volume":"194","author":"Assanto","year":"2021","journal-title":"Br J Haematol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1038\/s41375-021-01257-7","article-title":"Hairy cell leukemia and COVID-19 adaptation of treatment guidelines","volume":"35","author":"Grever","year":"2021","journal-title":"Leukemia"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.6004\/jnccn.2017.0165","article-title":"Hairy cell Leukemia, Version 2.2018: clinical practice guidelines in oncology","volume":"15","author":"Wierda","year":"2017","journal-title":"JNCCN J Natl Compr Cancer Netw"},{"key":"B22","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1093\/jnci\/djk030","article-title":"Second cancer incidence and cause-Specific mortality among 3104 patients with hairy cell leukemia: a population-based study","volume":"99","author":"Hisada","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"B23","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1200\/JCO.2002.20.3.638","article-title":"Risk of second cancer in patients with hairy cell leukemia: long-term follow-up","volume":"20","author":"Federico","year":"2002","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1610338","DOI":"10.3389\/pore.2022.1610338","article-title":"Case report: development of diffuse large B cell lymphoma a long time after hairy cell leukemia","volume":"28","author":"Nagy","year":"2022","journal-title":"Pathol Oncol Res"},{"key":"B25","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3390\/hematolrep14020020","article-title":"Prompt hematological recovery in response to a combination of pegylated interferon \u03b1-2a and rituximab in a profoundly immuno-suppressed hairy cell leukemia patient with a mycobacterial infection at onset: benefits and drawbacks of rapid immune reconstitution","volume":"14","author":"Furlan","year":"2022","journal-title":"Hematol Rep"},{"key":"B26","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3390\/jcm12010193","article-title":"A frail hairy cell leukemia patient successfully treated with pegylated interferon-\u03b1-2A","volume":"12","author":"De Novellis","year":"2023","journal-title":"J Clin Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"4706","DOI":"10.1182\/blood-2010-08-258772","article-title":"The renaissance of interferon therapy for the treatment of myeloid malignancies","volume":"117","author":"Kiladjian","year":"2011","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","first-page":"769628","DOI":"10.3389\/fonc.2021.769628","article-title":"Recent progress in interferon therapy for myeloid malignancies","volume":"11","author":"Healy","year":"2021","journal-title":"Front Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1089\/107999002760274845","article-title":"IFN-\u03b1\/\u03b2 receptor interactions to biologic outcomes: understanding the circuitry","volume":"22","author":"Brierley","year":"2002","journal-title":"J Interf Cytokine Res"},{"key":"B30","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1023\/A:1023668705040","article-title":"Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis","volume":"8","author":"Chawla-Sarkar","year":"2003","journal-title":"Apoptosis"}],"container-title":["Pathology and Oncology Research"],"original-title":[],"link":[{"URL":"https:\/\/www.por-journal.com\/articles\/10.3389\/pore.2025.1612108\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T08:41:10Z","timestamp":1747816870000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.por-journal.com\/articles\/10.3389\/pore.2025.1612108\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,21]]},"references-count":30,"alternative-id":["10.3389\/pore.2025.1612108"],"URL":"https:\/\/doi.org\/10.3389\/pore.2025.1612108","relation":{},"ISSN":["1532-2807"],"issn-type":[{"value":"1532-2807","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,21]]},"article-number":"1612108"}}